You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The IMCB-A!maginostic Joint Lab of Excellence will provide AI- and machine learning-based solutions to support computational digital and multiplex pathology.
The extended deal covers multiple blood cancer and solid tumor indications and will leverage several HalioDx technologies and approaches.
The firms are collaborating to provide reference architectures for whole-slide image viewing and managing to healthcare and life sciences organizations.
The firm said that receipt of the CE mark accelerates its entry into the diagnostic pathology market in Europe and other key geographies globally.
The team will combine Akoya's Vectra Polaris system with Precision for Medicine's Apostream tool to validate companion diagnostics and assess drug efficacy.
The acquisition of immunohistochemistry services provider QualTek will augment Discovery's existing histopathology services, the company said.
The method uses DESI-MS imaging to analyze fine-needle aspiration biopsies and could help evaluate cases where traditional cytology is inconclusive.
Pathologie-DNA will implement the anatomic and clinical pathology online support system, which is used to decide which ancillary tests to run on patients.
The company is currently partnering with three medical firms to develop its nonlinear optical spectroscopy technology for biosensing and imaging applications.
With two FDA-cleared platforms available, the technology is drawing clinicians interested in reaping its near-term benefits while preparing for its future impact.
The center will initially use the system for prostate, and head and neck cancers and in the future will let LabCorp patients access Mount Sinai pathologists.
The digital pathology system can be used for primary diagnosis as a result of the 510(k) clearance, which followed a multicenter study conducted at five clinical sites.
The approach makes use of a microfluidic probe that allows researchers to more effectively collect data on the kinetics of antibody-target reactions.
The Boston-based company said it will use the funding in part to continue refining its artificial intelligence-powered pathology research platform.
The firm said that it will use the funding to support business activities to meet demand for its approach to clinical trial recruitment.
The companies anticipate providing services that combine Flagship’s biomarker development and Indivumed’s multiplex IHC assay development capabilities.
The device, called the MasSpec Pen, was developed by University of Texas researchers to help more quickly and accurately assess margins during cancer surgery.
The partnership will accelerate the development of molecular diagnostics in the Chinese market, Minneapolis-based Bio-Techne said.
According to the researchers, the method could enable higher-throughput analyses while removing some of the subjectivity inherent in pathology practice.
The firms launched OptraScan's Global TelePath Network in the UAE, India, and South Africa under the partnership, named Neuberg Digipath, Powered by OptraScan.